Scratching beyond the surface: Here’s all you need to know about Atopic Dermatitis
Atopic Dermatitis, commonly called Eczema, affects millions globally with cases rising in India. Misunderstandings about its ...
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...
emjreviews.com2d
Impact of Atopic Dermatitis Depends on Age of Onset: EADV 2024
Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...
Everyday Health11d
Ebglyss, a New Biologic Treatment for Atopic Dermatitis, Gets FDA Approval
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
Business Wire4d
EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability i…
Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...
Medindia3d
FDA Approves EBGLYSS Drug for Atopic Dermatitis in Adults and Children
EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...
Lilly Reports New Long-term Data For Its Atopic Dermatitis Treatment Ebglyss
(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.
dermatologyadvisor2d
HORIZON: Rocatinlimab Effective in Adults With Atopic Dermatitis
Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
The American Journal of Managed Care13d
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of ...
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...